Einar K. Kristoffersen

Prof. Dr. Einar K. Kristoffersen

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
SSSiddharth Shanbhag
Siddharth Shanbhag
CKCarina Kampleitner
Carina Kampleitner
NANiyaz AlSharabi
Niyaz AlSharabi
SMSamih Mohamed-Ahmed
Samih Mohamed-Ahmed
Karol Ali Apaza AlccayhuamanKarol Ali Apaza Alccayhuaman
Karol Ali Apaza Alccayhuaman
RGReinhard Gruber
Reinhard Gruber
Functionalizing biomaterials with conditioned media (CM) from mesenchymal stromal cells (MSC) is a promising strategy for enhancing the outcomes of guided bone regeneration (GBR). This study aimed to evaluate the bone regenerative potential of collagen membranes (MEM) functionalized with CM from human bone marrow MSC (MEM-CM) in critical size rat calvarial defects. MEM-CM prepared via soaking (CM-SOAK) or soaking followed by lyophilization (CM-LYO) were applied to critical size rat calvarial defects. Control treatments included native MEM, MEM with rat MSC (CEL) and no treatment. New bone formation was analyzed via micro-CT (2 and 4 weeks) and histology (4 weeks). Greater radiographic new bone formation occurred at 2 weeks in the CM-LYO group vs. all other groups. After 4 weeks, only the CM-LYO group was superior to the untreated control group, whereas the CM-SOAK, CEL and native MEM groups were similar. Histologically, the regenerated tissues showed a combination of regular new bone and hybrid new bone, which formed within the membrane compartment and was characterized by the incorporation of mineralized MEM fibers. Areas of new bone formation and MEM mineralization were greatest in the CM-LYO group. Proteomic analysis of lyophilized CM revealed the enrichment of several proteins and biological processes related to bone formation. In summary, lyophilized MEM-CM enhanced new bone formation in rat calvarial defects, thus representing a novel ‘off-the-shelf’ strategy for GBR.

2 June 2009 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
AOAstrid Marta Olsnes
Astrid Marta Olsnes
EEElisabeth Ersvær
Elisabeth Ersvær
ARAnita Ryningen
Anita Ryningen
KPKristin Paulsen
Kristin Paulsen
PHPeter Hampson
Peter Hampson
Øystein BruserudØystein Bruserud
Øystein Bruserud
Summary: Acute myeloid leukaemia (AML) cells show constitutive release of several chemokines that occurs in three major clusters: (I) chemokine (C‐C motif) ligand (CCL)2–4/chemokine (C‐X‐C motif) ligand (CXCL)1/8, (II) CCL5/CXCL9–11 and (III) CCL13/17/22/24/CXCL5. Ingenol‐3‐angelate (PEP005) is an activator of protein kinase C and has antileukaemic and immunostimulatory effects in AML. We investigated primary AML cells derived from 35 unselected patients and determined that PEP005 caused a dose‐dependent increase in the release of chemokines from clusters I and II, including several T cell chemotactic chemokines. The release of granulocyte‐macrophage colony‐stimulating factor and hepatocyte growth factor was also increased. CCL2–4/CXCL1/8 release correlated with nuclear factor (NF)‐κB expression in untreated AML cells, and PEP005‐induced chemokine production was associated with further increases in the expression of the NF‐κB subunits p50, p52 and p65. Increased DNA binding of NF‐κB was observed during exposure to PEP005, and the specific NF‐κB inhibitor BMS‐345541 reduced constitutive chemokine release even in the presence of PEP005. Finally, PEP005 decreased expression of stem cell markers (CD117, CXCR4) and increased lineage‐associated CD11b and CD14 expression. To conclude, PEP005 has a unique functional pharmacological profile in human AML. Previous studies have described proapoptotic and T cell stimulatory effects and the present study describes additional T cell chemotactic and differentiation‐inducing effects.

Verified
Journal Article
Open access
PDF file
NANiyaz AlSharabi
Niyaz AlSharabi
RGReinhard Gruber
Reinhard Gruber
Mariano SanzMariano Sanz
Mariano Sanz
SMSamih Mohamed-Ahmed
Samih Mohamed-Ahmed
EKEinar K. Kristoffersen
Einar K. Kristoffersen
SSSiddharth Shanbhag
Siddharth Shanbhag
Secretomes of mesenchymal stromal cells (MSCs) are emerging as a novel growth factor (GF)-based strategy for periodontal and bone regeneration. The objective of this study was to compare the secretome of human bone marrow MSC (BMSC) to that of leukocyte- and platelet-rich fibrin (L-PRF), an established GF-based therapy, in the context of wound healing and regeneration. Conditioned media from human BMSCs (BMSC-CM) and L-PRF (LPRF-CM) were subjected to quantitative proteomic analysis using liquid chromatography with tandem mass spectrometry. Global profiles, gene ontology (GO) categories, differentially expressed proteins (DEPs), and gene set enrichment (GSEA) were identified using bioinformatic methods. Concentrations of selected proteins were determined using a multiplex immunoassay. Among the proteins identified in BMSC-CM (2157 proteins) and LPRF-CM (1420 proteins), 1283 proteins were common. GO analysis revealed similarities between the groups in terms of biological processes (cellular organization, protein metabolism) and molecular functions (cellular/protein-binding). Notably, more DEPs were identified in BMSC-CM (n = 550) compared to LPRF-CM (n = 118); these included several key GF, cytokines, and extracellular matrix (ECM) proteins involved in wound healing. GSEA revealed enrichment of ECM (especially bone ECM)-related processes in BMSC-CM and immune-related processes in LPRF-CM. Similar trends for intergroup differences in protein detection were observed in the multiplex analysis. Thus, the secretome of BMSC is enriched for proteins/processes relevant for periodontal and bone regeneration. The in vivo efficacy of this therapy should be evaluated in future studies.

20 March 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
LTLiv Cecilie Vestrheim Thomsen
Liv Cecilie Vestrheim Thomsen
AHAlfred Honoré
Alfred Honoré
LRLars Anders Rokne Reisæter
Lars Anders Rokne Reisæter
BABjarte Almås
Bjarte Almås
ABAstrid Børretzen
Astrid Børretzen
CBChristian Beisland
Christian Beisland
Metastatic castration-resistant prostate cancer (mCRPC) is an immunologically cold disease with dismal outcomes. Cryoablation destroys cancer tissue, releases tumor-associated antigens and creates a pro-inflammatory microenvironment, while dendritic cells (DCs) activate immune responses through processing of antigens. Immunotherapy combinations could enhance the anti-tumor efficacy. This open-label, single-arm, single-center phase I trial determined the safety and tolerability of combining cryoablation and autologous immature DC, without and with checkpoint inhibitors. Immune responses and clinical outcomes were evaluated. Patients with mCRPC, confirmed metastases and intact prostate gland were included. The first participants underwent prostate cryoablation with intratumoral injection of autologous DCs in a 3 + 3 design. In the second part, patients received cryoablation, the highest acceptable DC dose, and checkpoint inhibition with either ipilimumab or pembrolizumab. Sequentially collected information on adverse events, quality of life, blood values and images were analyzed by standard descriptive statistics. Neither dose-limiting toxicities nor adverse events > grade 3 were observed in the 18 participants. Results indicate antitumor activity through altered T cell receptor repertoires, and 33% durable (> 46 weeks) clinical benefit with median 40.7 months overall survival. Post-treatment pain and fatigue were associated with circulating tumor cell (CTC) presence at inclusion, while CTC responses correlated with clinical outcomes. This trial demonstrates that cryoimmunotherapy in mCRPC is safe and well tolerated, also for the highest DC dose (2.0 × 108) combined with checkpoint inhibitors. Further studies focusing on the biologic indications of antitumor activity and immune system activation could be considered through a phase II trial focusing on treatment responses and immunologic biomarkers.

11 May 2023 in Vox Sanguinis
Verified
Journal Article
Open access
HBHanne Braathen
Hanne Braathen
TLTurid Helen Felli Lunde
Turid Helen Felli Lunde
JAJörg Assmus
Jörg Assmus
KHKristin Gjerde Hagen
Kristin Gjerde Hagen
EKEinar K. Kristoffersen
Einar K. Kristoffersen
TATorunn Oveland Apelseth
Torunn Oveland Apelseth
Background and Objectives: Based on previous success using apheresis platelets, we wanted to investigate the in vitro quality and platelet function in continuously cold‐stored and delayed cold‐stored platelet concentrates (PCs) from interim platelet units (IPUs) produced by the Reveos system.Materials and Methods: We used a pool‐and‐split design to prepare 18 identical pairs of PCs. One unit was stored unagitated and refrigerated after production on day 1 (cold‐stored). The other unit was stored agitated at room temperature until day 5 and then refrigerated (delayed cold‐stored). Samples were taken after pool‐and‐split on day 1 and on days 5, 7, 14 and 21. Swirling was observed and haematology parameters, metabolism, blood gas, platelet activation and platelet aggregation were analysed for each sample point.Results: All PCs complied with European recommendations (EDQM 20th edition). Both groups had mean platelet content >200 × 109/unit on day 21. The pH remained above 6.4 for all sample points. Glucose concentration was detectable in every cold‐stored unit on day 21 and in every delayed cold‐stored unit on day 14. The cold‐stored group showed a higher activation level before stimulation as measured by flow cytometry. The activation levels were similar in the two groups after stimulation. Both groups had the ability to form aggregates after cold storage and until day 21.Conclusion: Our findings suggest that PCs from IPUs are suitable for cold storage from day 1 until day 21 and delayed cold storage from day 5 until day 14.

23 July 2019 in ISBT Science Series
Verified
Journal Article
Open access
PDF file
EKEinar K. Kristoffersen
Einar K. Kristoffersen
TATorunn Oveland Apelseth
Torunn Oveland Apelseth
Whole blood is currently being reintroduced as a blood product to be used in massive bleeding situations because it affords plasma, red cells and platelets in a balanced ratio and in a logistical advantageous way. Questions concerning the haemostatic potential of the platelets have arisen, especially in cold‐stored whole blood, as this is the major whole blood product in use. When reviewing current knowledge on this, there is an abundance of publications demonstrating that in vitro, platelets in cold‐stored whole blood have a haemostatic capacity up to 14 days, and even after 21 and 35 days of storage depending on type of additive solution. There is a paucity of data on clinical trials of cold‐stored platelets, whereas there is an abundance of previous clinical experience with whole blood, both cold‐stored and fresh, as an efficacious and safe product for use in pre‐ and in‐hospital patients with life‐threatening bleeding.